Quick Overview
QRISK3 is the UK's validated cardiovascular disease (CVD) risk prediction tool, estimating 10-year risk of heart attack or stroke in patients aged 25-84 without pre-existing CVD. NICE NG238 mandates its use for primary prevention decisions, particularly statin initiation. Understanding when to calculate, interpret thresholds, and implement risk modification is essential for reducing cardiovascular morbidity and mortality.
Core Facts & Concepts
When to Calculate QRISK3:
- Patients aged 25-84 years without established CVD (no prior MI, angina, stroke, TIA, PVD)
- Exclude: Type 1 diabetes, CKD eGFR <60, familial hypercholesterolaemia (automatic high-risk)
- Opportunistic screening or symptomatic assessment (e.g., hypertension, dyslipidaemia)
- Repeat calculation every 5 years if low risk, or annually if score 5-10%
Risk Interpretation & Thresholds:
- ≥10% = High risk → Offer atorvastatin 20mg for primary prevention (NICE NG238)
- 5-10% = Moderate risk → Discuss lifestyle modification, consider statin if additional factors present
- <5% = Low risk → Reassure, reinforce lifestyle advice
QRISK3 Variables (17 factors):
- Demographics: Age, sex, ethnicity, postcode (Townsend deprivation score)
- Clinical: BMI, systolic BP, cholesterol/HDL ratio, diabetes status, smoking
- Conditions: CKD, atrial fibrillation, rheumatoid arthritis, migraine, severe mental illness
- Medications: Antihypertensives, corticosteroids
📌 Remember: QRISK3 ≥10% = Statin Start - Primary prevention threshold for atorvastatin 20mg
Problem-Solving Approach
Step-by-Step Risk Assessment:
- Identify eligibility → Age 25-84, no CVD, not automatic high-risk (T1DM/CKD/FH)
- Gather data → BP, lipid profile (non-fasting acceptable), BMI, smoking status, comorbidities
- Calculate QRISK3 → Use online calculator (qrisk.org) with all 17 variables
- Interpret score → <5% (low), 5-10% (moderate), ≥10% (high)
- Discuss findings → Explain absolute risk in plain language ("10 in 100 chance over 10 years")
- Offer interventions → Lifestyle first-line for all; statin if ≥10%
Statin Initiation Criteria (NICE NG238):
- QRISK3 ≥10% → Offer atorvastatin 20mg once daily
- Assess adherence, drug interactions, contraindications (active liver disease)
- Measure lipids 3 months post-initiation → Aim for ≥40% reduction in non-HDL cholesterol
🚩 Red Flags Requiring Specialist Referral:
- Total cholesterol >9 mmol/L or non-HDL >7.5 mmol/L (possible familial hypercholesterolaemia)
- Premature CVD family history (<60 years in first-degree relative)
- Triglycerides >10 mmol/L (pancreatitis risk)
Analysis Framework
Risk Modification Strategies Beyond Statins:
| Category | Intervention | Impact on CVD Risk |
|---|---|---|
| Smoking | Complete cessation | ↓ 30-50% within 2 years |
| Diet | Mediterranean diet, ↓ saturated fat <10% calories | ↓ 10-20% |
| Exercise | 150 min moderate/week (brisk walking) | ↓ 20-30% |
| Weight | BMI 20-25 kg/m², waist <94cm (M), <80cm (F) | ↓ 10-15% |
| BP control | Target <140/90 mmHg (<80 if high risk) | ↓ 20-25% per 10mmHg reduction |
| Alcohol | ≤14 units/week, spread over 3+ days | Variable benefit |
| Diabetes control | HbA1c <53 mmol/mol (if non-diabetic) | ↓ 15-20% |
Shared Decision-Making Factors:
- Patient preference, health literacy, life expectancy
- Competing comorbidities (frailty, limited prognosis)
- Potential statin side effects (myalgia 5-10%, rare rhabdomyolysis)
Visual Aid
| QRISK3 Score | Management | Follow-up |
|---|---|---|
| <5% | Lifestyle modification only | Reassess in 5 years |
| 5-10% | Lifestyle + discuss statin | Annual reassessment |
| ≥10% | Lifestyle + atorvastatin 20mg | Lipids at 3 months, annual review |
Key Points Summary
✓ QRISK3 ≥10% is the threshold for offering atorvastatin 20mg in primary prevention (NICE NG238)
✓ Exclude automatic high-risk groups (T1DM, CKD stages 3-5, familial hypercholesterolaemia) - offer statin without QRISK3
✓ Calculate QRISK3 using 17 variables including demographics, BP, lipids, smoking, comorbidities
✓ Target ≥40% reduction in non-HDL cholesterol at 3 months post-statin initiation
✓ Lifestyle modification (smoking cessation, Mediterranean diet, 150 min exercise/week) reduces CVD risk by 30-50%
✓ 🚩 Refer if: Total cholesterol >9 mmol/L, premature family history, or triglycerides >10 mmol/L
✓ Reassess low-risk patients every 5 years; moderate-risk annually
⚠️ Warning: QRISK3 underestimates risk in South Asian populations and those with severe mental illness - consider lower threshold for intervention